Blog
Cancer R&D's tenuous value chain
To succeed in oncology drug development, Pharma execs need new approaches to clinical trials, diagnostics and pricing.
In defense of pharma forecasting
The problem isn't with Pharma forecasts – it's with how they're communicated and used in decision-making.
A victim of his success: Malcolm Gladwell's "David and Goliath"
Let's get one thing out of the way: if you're a Gladwell hater, this book will not change your mind.
Clinical trial transparency - The road ahead
There's lots of work to do in trial registration, results dissemination, and data access. Let's get cracking.
The Mystery of McKinsey: Review of "The Firm" by Duff McDonald
Almost 100 years since its founding, we're still no closer to answering the age-old question about McKinsey: Are they worth it?
Pharma's Kodak moment
The demise of the storied photography firm shows how the links in a value chain can become decoupled under one's feet. What does this mean for Pharma?
Disclosure of trial results - a continuing saga
It's time to bring data to the mud-slinging debate over disclosure of clinical trial results. A recent article provides a good starting point.
New drugs less effective than old ones? Not so fast (continued)
A recently-published screed about pharma R&D plumbs new depths in pharmascolding. Let's see if it holds up to scrutiny. (Want to take a wild guess?)
How to cure cancer? A review of "The Truth in Small Doses" by Clifton Leaf
Leaf's book is a powerful call to action to focus on the "C" word in oncology - "cure".
Why oncology companies should care about drug adherence
Many companies think adherence isn't an issue in cancer care. They're wrong.